Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ model

MLA

Evan Flietner, et al. “Ponatinib Sensitizes Myeloma Cells to MEK Inhibition in the High-Risk VQ Model.” Scientific Reports, vol. 12, no. 1, June 2022, pp. 1–10. EBSCOhost, https://doi.org/10.1038/s41598-022-14114-z.

APA

Evan Flietner, Zhi Wen, Adhithi Rajagopalan, Oisun Jung, Lyndsay Watkins, Joshua Wiesner, Xiaona You, Yun Zhou, Yuqian Sun, Brock Kingstad-Bakke, Natalie S. Callander, Alan Rapraeger, M. Suresh, Fotis Asimakopoulos, & Jing Zhang. (2022). Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ model. Scientific Reports, 12(1), 1–10. https://doi.org/10.1038/s41598-022-14114-z

Chicago

Evan Flietner, Zhi Wen, Adhithi Rajagopalan, Oisun Jung, Lyndsay Watkins, Joshua Wiesner, Xiaona You, et al. 2022. “Ponatinib Sensitizes Myeloma Cells to MEK Inhibition in the High-Risk VQ Model.” Scientific Reports 12 (1): 1–10. doi:10.1038/s41598-022-14114-z.